Bispecifics, Trispecifics and Beyond: Shaping the Next Wave of Global Drug Innovation

ABOUT THE EVENT

Date: Tuesday, November 17, 2026 11:50am EST
Event Location: Virtual

As antibody-based therapies continue to evolve, multispecific therapeutics are moving beyond early scientific concepts toward clinical development and commercialization. Recent advances, from head-to-head clinical data for PD-1/VEGF bispecifics to emerging bispecific ADCs, TL1A-targeting therapies, and trispecific T-cell engagers, highlight the growing potential of multispecific approaches across a range of disease areas.
Yet significant challenges remain. As competition intensifies and pipelines become increasingly crowded, questions around clinical validation, therapeutic differentiation, molecular design, CMC development, and scalable manufacturing are becoming more critical. At the same time, growing global interest in innovative biotech assets is creating new opportunities for licensing and cross-border collaboration, while introducing new challenges and risks.
Against this backdrop, the China BioPioneers: International Edition panel, co-hosted by AsymBio, ISWTC (InScienceWeTrust Community), Healthcare Executive, and Weijieyao, brings together biotech executives and industry experts to discuss the evolving multispecific therapeutics landscape and its implications for global drug development.
The discussion will explore where multispecific therapies stand today, how the next generation can achieve meaningful differentiation, the role of CMC in enabling successful development, and the opportunities for global collaboration.
What We Will Cover:

  • Why Bispecifics and Trispecifics? – The unique value of multispecific designs beyond monoclonal antibodies
  • Design Decisions That Make or Break a Multispecific
  • CMC as a Strategy – How manufacturing can become a competitive advantage
  • Why Are Western Pharma, Biotech, and Investors Drawn to Chinese Multispecific Assets?
  • Beyond Oncology and Immunology: Where Will Multispecifics Deliver Next?

Featured Panelists:

  • Jing Li, Founder and CEO of VelaVigo
  • Stephen Yoder, CEO of Red Ridge Bio
  • Liangsu Wang, Co-Founder and CSO of Caldera Therapeutics
  • Zhen Su, President and CEO of Marengo Therapeutics
  • DanDan Dong, Managing Partner of TCGX Capital

Moderator:

  • Leon “Jun” Tang, PhD, MS, ISWT Community
MORE EVENTS
This year tested many of the assumptions underpinning biotech forecasts. While analysts correctly identified several emerging trends, ongoing capital constraints, widening capability gaps and the growing importance of global development revealed a more complex reality than many expected. This webinar explores which predictions proved most accurate, where expectations diverged from market conditions and what those outcomes can teach leaders planning for 2027.
Tuesday, December 8, 2026 12–1pm EST
 · 
Virtual